Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction With the Drug-eluting Resorbable Magnesium Scaffold: the BEST-MAG Multicentre Study

What this Trial Is About

Researchers are investigating the use of a bioresorbable magnesium scaffold called Magmaris for treating patients with ST-segment elevation myocardial infarction (STEMI), a type of heart attack. This study explores the potential advantages of Magmaris over permanent bare-metal or drug-eluting stents due to its ability to dissolve over time. Early findings suggest Magmaris may have a lower risk of blood clots compared to other bioresorbable scaffolds, making it a promising option for patients with STEMI. Participants will receive the Magmaris resorbable magnesium scaffold implanted in the affected coronary artery segment. The study involves a single treatment group where all STEMI patients receive this device. The research includes intracoronary imaging with optical coherence tomography (OCT) to monitor the vessel and scaffold, with follow-up procedures planned to assess vessel healing and device performance. During the study, participants will be monitored for outcomes such as cardiac death, heart attacks related to the treated vessel, and the need for further procedures on the target lesion within 12 months. Additional evaluations include procedural success, scaffold thrombosis, and broader cardiac events up to two years. Imaging with OCT at 15 months will assess vessel healing. The total study duration includes regular follow-ups over two years, ensuring close observation of safety and effectiveness measures.

OCT Guided Magmaris RMS in STEMI